← FDA DRUG APPROVALS

FDA ANDA · ANDA065325

AMOXICILLIN

Sponsor: HIKMA

APPLICATION
ANDA065325
TYPE
ANDA
ORIGINAL APPROVAL
2006-06-19
LATEST ACTION
2024-05-01
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

AMOXICILLINPrescription
AMOXICILLIN 400MG/5ML · FOR SUSPENSION · ORAL
AMOXICILLINPrescription
AMOXICILLIN 200MG/5ML · FOR SUSPENSION · ORAL

Approval history

2024-05-01Labeling · Supplement 35 · standardAP
2024-04-25Labeling · Supplement 32 · standardAP
2014-12-02Labeling · Supplement 16 · standardAP
2014-12-02Labeling · Supplement 17 · standardAP
2013-03-07Labeling · Supplement 11AP
2008-10-30Labeling · Supplement 3AP
2006-06-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →